Summary A randomised study was conducted in 62 patients with advanced breast cancer to assess whether granulocyte-macrophage colony-stimulating factor (GM-CSF) would yield an increase in the dose intensity of a standard-dose CEF regimen through an acceleration of chemotherapy administration. Patients received CEF (cyclophosphamide 600 mg m'2, epidoxorubicin 60 mg m-2 and fluorouracil 600 mg m-2) i.v. on day 1 or the same chemotherapy, plus GM-CSF 1Ol g kg-I s.c. starting from day 4, repeated as soon as haematopoietic recovery from nadir occurred. Patients in the CEF + GM-CSF group received chemotherapy at a median interval of 16 days compared with 20 days in the control group. This led to a significant increase (P = 0.02) in the dose intensity actually administered in the third, fourth and sixth cycles: +28%, +25%, +20% respectively. Non-haematological toxicity was mild. GM-CSF had to be reduced or suspended in 50% of patients because of toxicity. Haematological toxicity, mainly cumulative anaemia and thrombocytopenia, was manageable. An increase in response rate for patients with measurable disease, of borderline statistical significance (P= 0.088, P for trend = 0.018), from 42% in the CEF group to 69% in the CEF + GM-CSF group, was observed. This randomised trial indicates that GM-CSF is useful for chemotherapy acceleration. Accelerated CEF + GM-CSF is a moderately dose-intensive regimen that can be administered in an outpatient clinic and is associated with a high objective response.
No dramatic improvements in the treatment of metastatic breast cancer have been achieved in the last decade. First-line standard combination chemotherapy induces objective remissions in 40-70% of patients, but only 10-20% of these responses are complete. No cure has been achieved and overall survival has not been modified, being still 24 months on average. However, this lack of progress does not reflect a plateau in research efforts. New drugs, ideas and strategies have been developed and tested in the clinical setting. Among these, the role of dose intensity, defined as the amount of drug given per unit time, has been extensively debated (Hryniuk et al., 1984; Henderson et al., 1988) . Arguments for and against its relevance are based essentially on retrospective analyses (Hryniuk et al., 1984; Bonadonna et al., 1981) or on randomised trials that were actually designed to test standard vs low dose intensity rather than standard vs high dose intensity regimens. Analysis of results from randomised studies testing the value of the dose or dose intensity, without bone marrow support, clearly reveals that myelosuppression is the dose-limiting factor hindering the administration of higher than standard dose intensities. However, the recent availability of haematopoietic colony-stimulating factors (CSFs), a family of glycoproteins that support the proliferation and differentiation of haematopoietic progenitors, could overcome this limitation. Phase I and II trials have been conducted by using granulocyte-macrophage and granulocyte CSF (GM-CSF and G-CSF) alone or in combination with chemotherapy. These studies have indicated the ability of GM-CSF and G-CSF to reduce the severity of leucocyte nadir and to shorten the duration of leucopenia after standard chemotherapy (Demetri et al., 1992; Kaplan et al., 1991) . These findings have led to the incorporation of GM-CSF and G-CSF in chemotherapy programmes in an attempt to increase the dose intensity without the need for bone marrow and/or peripheral stem cell transplantation. Three possible means to increase dose intensity can be considered: increasing the dose, shortening the interval between cycles or a combination of both. Among these, we have chosen to pursue the second. The scientific rationale of this strategy stems from the observation that, by using G-CSF or GM-CSF, leucocyte nadir is anticipated and recovery hastened, while the depth of the nadir is only slightly affected (Hoekman et al., 1991; Logothetis et al., 1990; Gabrilove et al., 1988; Hamm et al., submitted) . Pilot studies carried out in patients with small-cell lung carcinoma (Ardizzoni et al., 1990 (Ardizzoni et al., , 1993 suggest that GM-CSF is indeed able to allow an increase in the frequency of chemotherapy administration. However, the amount of dose intensity increase achievable is only around 30% and the question may be posed as to whether the growth factor is really needed to obtain such an increase in dose intensity. Therefore, before starting randomised trials aimed at assessing the clinical impact of chemotherapy acceleration, it seemed important to verify, in a prospective randomised fashion, whether this type of dose intensity increase would actually require the concomitant use of GM-CSF.
Based on previous experiences carried out at the Istituto Nazionale per la Ricerca sul Cancro of Genoa (Conte et al., 1987; 1990) , a combination of cyclophosphamide, 5-fluorouracil and epidoxorubicin (CEF) was chosen to address this question in advanced breast cancer.
The primary objective of the study was to compare the CEF dose intensity achieved with and without GM-CSF. Since chemotherapy doses were the same in both groups, the study was designed to test whether the addition of GM-CSF would allow a significant increase in CEF dose intensity through an acceleration of chemotherapy administration. Secondary objectives of the study were to compare the two treatment groups in terms of both toxicity and anti-tumour activity.
Patients and methods

Eligibility
Eligible patients were women aged 18-65 years with histologically confirmed stage IlIb or IV ( AM Joint Committee, 1981) carcinoma of the breast. Patients who had received prior chemotherapy for advanced disease or patients who had finished adjuvant chemotherapy less than 12 months before randomisation were not eligible for the study. Prior hormonal therapy and prior limited radiotherapy (involving no more than 30% of the functioning bone marrow) were permitted.
Eligible patients were also required to have a WHO performance score <3 and to be mentally and geographically suitable for the study. Patients with clinical or radiological evidence of brain metastases, those who were pregnant and those who had previously been treated with haemopoietic growth factors were excluded. Additional eligibility criteria included adequate haematological [white blood cells (WBC) > 3 x I09 1' and/or absolute neutrophil count (ANC) > 2 x I09 I-' , platelet (PLT) > 100 x I09 I-' and haemoglobin level (Hb) > 9.5 g dl-'], renal (creatinine level < 1.4 mg dl-') and hepatic (bilirubin level > 1.4 mg dl-') function, adequate cardiac function (no clinical evidence of congestive heart failure, symptoms of coronary artery disease, serious cardiac arrhythmias, prior myocardial infarction on ECG or pericarditis) and no evidence of active infection.
Study design and treatment
Patients were randomised to receive a chemotherapy regimen consisting of cyclophosphamide (CTX) 600 mg m-2, epidoxorubicin (EpiDX) 60 mg m-2 and 5-fluorouracil (FU) 600 mg m-2 given by intravenous bolus on day 1 on an ambulatory basis or the same chemotherapy combined with GM-CSF (Schering-Plough/Sandoz) self-administered subcutaneously at a dose of 10 tg kg-' from day 4 (because of the long plasma clearance of EpiDX) until adequate haematopoietic recovery (WBC > 3 x I09 Il and/or ANC > 2 x 109 1-h', PLT > 100X 109 1' and Hb > 9.5 g dl-'). In both groups the time of recycle was not fixed but chemotherapy had to be repeated as soon as haemopoietic recovery occurred. In patients receiving GM-CSF, 1 day's rest was required between the last growth factor administration and the next chemotherapy course. In patients in whom nadir haematological toxicity did not occur, a minimum interval between chemotherapy courses of 10 days had to be observed.
A 25% chemotherapy dose reduction, in subsequent courses, was considered only in the case of grade IV nonhaematological toxicity or in case of grade IV haematological toxicity associated with one of the following complications: anaemia with heart failure, febrile neutropenia or documented infection, bleeding.
In metastatic patients, chemotherapy was continued for at least six courses unless progressive disease or life-threatening toxicity occurred. A further four courses could be given in responsive patients at the discretion of the investigator to achieve a maximum of ten chemotherapy cycles or chemotherapy was continued until best response was achieved plus two courses. Locally advanced patients were treated with induction chemotherapy until best response was reached, with a maximum of six cycles, then radical surgery was performed, if indicated.
Prophylactic ciprofloxacin 500 mg b.i. and red blood cell transfusions with Hb values below 9 g dl-'. The use of corticosteroids was allowed only as antiemetic treatment during chemotherapy administration. Paracetamol was administered whenever required to control bone pain and fever induced by GM-CSF. HI antagonists were given to patients with allergic reactions related to GM-CSF administration. In case of grade III-IV toxicity attributable to GM-CSF, the growth factor was first withdrawn until side-effects subsided and then resumed at a dose of 5 tLg kg-'. Whenever, despite the dose reduction, toxicity was still present, GM-CSF was suspended and chemotherapy continued outside the protocol.
The study was accepted by the Protocol Review Committee of the Istituto Nazionale per la Ricerca sul Cancro and of each collaborating centre. Informed consent was verbally obtained from all the patients before study entry. The study was carried out at the Istituto Nazionale per la Ricerca sul Cancro of Genoa and in four other collaborating institutes.
Monitoring
At the start of therapy patients underwent history and physical examination, including tumour measurement, chest radiographs, complete blood count and serum chemistry, tumour markers, liver ultrasound, bone nuclear scan, ECG and bone marrow aspiration and/or biopsy. During treatment patients were required to have a complete blood count at least twice a week. Serum chemistries and tumour markers were repeated every two cycles, while chest radiography, liver ultrasound and bone nuclear scan were repeated every 2-3 cycles if needed for response assessment. Bone marrow aspiration/biopsy was repeated at the end of treatment only in patients with documented bone marrow metastases. Vital signs were checked before and 2 h after the first GM-CSF dose, which had to be administered in the outpatient clinic.
Criteria of tumour response and toxicity Tumour responses and toxicities were assessed according to WHO criteria (Miller et al., 1981) .
As tumour response was not the primary focus of the study, both patients with and without measurable disease were randomised. Therefore, tumour response was evaluated only in patients with measurable disease, and comparison of responses in the two treatment groups was limited to these patients.
Time to progression and overall survival were calculated from the first day of treatment.
Statistics and dose intensity calculation Randomisation was obtained by telephoning the Trial Office of the Istituto Nazionale per la Ricerca sul Cancro of Genova. Patients were stratified by institution only.
The main objective of the study was to compare the dose intensity achieved in the two treatment groups. Dose intensity, expressed in mg m-2 day-', was calculated for each drug as the total amount of drug given in mg divided by the body surface area and by the time in days elapsed between the start of the treatment and the day of the last chemotherapy course. Reference standard dose intensity was that of an equivalent regimen (same doses, same drugs) delivered at 3-week intervals. It was arbitrarily planned to perform dose intensity calculations at the third, fourth and sixth cycles.
Patients receiving > 130% of the standard dose intensity were considered as successes; all the others were defined as failures.
In analysing dose intensity results an 'intent to treat' criterion was applied. Therefore all patients were evaluated including those who in whom GM-CSF administration was reduced or suspended. Patients who did not receive at least two cycles of chemotherapy were excluded from the dose intensity calculation, but considered for statistical analysis as failures.
Fixing a = 0.05 and J = 0.10, and defining PI as the proportion of successes in the control group and P2 as the expected proportion of successes in the experimental group, the total number of patients to be accrued was calculated, for a two-tailed z-test for the comparison of proportions, based on the following considerations. It was estimated that in approximately one-third of the patients it is possible to administer the regimen being studied without GM-CSF at 130% of the standard dose intensity at the end of the sixth cycle. The doubling of this proportion appeared to be the minimal target worth detecting in this trial to justify further studies testing the clinical efficacy of such a dose intensity increase with GM-CSF in breast cancer patients. Therefore, setting PI to 0.35 and P2 to 0.70, the number of patients needed for this study was 92.
Owing to difficulties in obtaining drugs, analysis of results was done after 60 patients has been accrued. At this time, as a lower than expected proportion of successes was observed in the control group, it was decided to stop the accrual since the study had sufficient power to detect the target difference (33% difference in the proportion of successes). No adjustment for repeated analysis was planned.
Results
From July 1990 to April 1992, 62 patients entered the study. Their main characteristics are shown in Table I . Thirty patients were assigned to CTX, EpiDX and FU (CEF), and 32 patients to the same treatment plus GM-CSF (CEF + GM-CSF).
Four patients were not evaluated for toxicity and dose intensity calculation: two patients, one in each group, dropped out immediately after randomisation, and two patients in the CEF group received only one cycle of chemotherapy (one patient died from disseminated intravascular coagulation, another refused to continue chemotherapy). These four patients were recorded as failures for dose intensity analyses according to the study protocol. One additional patient was not evaluable for toxicity because of missing data.
In seven other patients in the CEF group and 11 patients in the CEF + GM-CSF group therapy was stopped before the sixth cycle. Reasons (Figure 2 ). In particular, at the sixth cycle only two patients (6.7%) in the CEF group satisfied the criteria of success, compared with ten patients (31.2%) in the CEF + GM-CSF group (P = 0.034). This difference was also statistically significant when only patients actually on therapy at that time were evaluated (P = 0.020).
A logistic regression analysis of factors predicting the probability of success was performed. The only independent factor significantly affecting dose intensity outcome was the assigned treatment, with patients receiving GM-CSF having a higher chance of achieving a dose intensity success at the sixth cycle. On the other hand, performance status, age, prior adjuvant chemotherapy, stage, histology and bone marrow involvement at entry were not important determinants of dose intensity in our study.
Chemotherapy toxicity and GM-CSF safety The incidence and degree of the most common toxicities are listed in Table III (Figure 3) .
In contrast, a statistically significant difference in thrombocytopenia and anaemia was observed. Nearly 32% of patients receiving CEF plus GM-CSF vs 7.1% in the CEF group had grade III/IV thrombocytopenia which was life-threatening (grade IV) in 14% and 0% of cases respectively. Moreover, 27.5% of patients in the CEF + GM-CSF group suffered from anaemia vs 3.5% in the CEF group. In the GM-CSF group, 43.4% cycles were associated with any grade of platelet toxicity, as compared with 19.5% in the CEF arm. Furthermore, thrombocytopenia and anaemia progressively worsened with increasing cycles of therapy in the CEF + GM-CSF group (Figure 3) patients treated with growth factors, only two hospitalisations were necessary because of febrile neutropenia, and no death from toxicity occurred.
Tumour response and survival Since measurable disease was not required as an entry criterion, the evaluation of response was performed only in patients with measurable tumour at the beginning of the study. Fifty-three patients were included in this analysis (Table IV) . There was evidence of an advantage in terms of objective responses (CR + PR) in the CEF + GM-CSF group, 68.9% (95% CI 49-85%) vs 41.6% (95% CI 22-63%), of borderline statistical significance (response vs no response: X for heterogeneity = 2.89, P = 0.088; test for trend over four strata of response: X for trend = 5.55, P = 0.018).
2,!r. The effect of age, performance status, stage, bone marrow invasion, dominant site of metastases, adjuvant therapy and assigned treatment (CEF vs CEF + GM-CSF) on response were analysed by a logistic regression procedure. The only two variables found to be independently associated with the probability of objective response were stage (coefficient -2.1 ± 1.2, P = 0.02) and treatment group (coefficient 1.3 ± 0.7, P = 0.05).
Median time to progression was 11 months for CEF and 14 months for CEF + GM-CSF (P = 0.41). So far 15 patients (50%) in the CEF group and nine patients (28.1%) in the CEF + GM-CSF group have died. The former had a median actuarial survival of 17 months. Median actuarial survival in GM-CSF arm has not been reached yet. The actuarial 2-year survival is 40% (95% CI 18-62%) and 67% (95% CI 49-85%) for CEF and CEF + GM-CSF respectively (X = 2.13, P=0.14). The long-term feasibility of acclerated CEF could also be demonstrated by the number of cycles administered. In fact, two-thirds of patients managed to receive at least six courses of chemotherapy, in both CEF and GM-CSF groups. The efficacy of GM-CSF in sustaining leucocyte recovery was constant throughout treatment. Despite the acceleration of chemotherapy achieved in the patients treated with GM-CSF, the median leucoycte nadir did not differ in the two groups in any of the chemotherapy courses.-On the contrary, most patients on GM-CSF developed cumulative anaemia and thrombocytopenia. This phenomenon has also been described in other studies (Hoekman et al., 1991; Hamm et al., submitted; Ardizzoni et al., 1993) . However, unlike previous reports, these toxicities were always manageable on an outpatient basis. Only one patient required platelet transfusion. Treatment with accelerated chemotherapy and GM-CSF was associated with a significantly higher incidence of moderate fatigue. This could be explained either by the acceleration of treatment itself or by the higher degree of anaemia and GM-CSF-related symptoms. Overall, toxicities related to the growth factor required dose reduction or suspension in 50% of patients. When we planned the study, the chosen dose of 10ltgkg-' was based on the fact that this dose had proved safe and effective in our previous pilot studies on accelerated chemotherapy (Ardizzoni et al., 1990; . More recent data (Hamm et al., submitted) and results from the present study would indicate that the dose of 5ttgkg-' might be preferable in addition to moderately dose-intensive programmes. The issue of dose intensity impact on the clinical outcome of breast cancer patients is still a matter of controversy. Hryniuk and Bush (1991) first observed in a retrospective study the direct correlation between dose intensity and clinical outcome in advanced breast cancer. We are aware of at least 11 randomised trials that have prospectively explored the role of dose or dose intensity in advanced breast cancer (Tannock et al., 1988; Habeshaw et al., 1991; Carmo-Peirera et al., 1987; Hoogstraten et al., 1976; O'Bryan et al., 1977; Forastiere et al., 1982; Beretta et al., 1986; Hortobagyi et al., 1987; Ebbs et al., 1989; Becher et al., 1990; Focan et al., 1990) . Seven of these, actually addressed the value of standard, or almost standard, doses of chemotherapy compared with low doses (Tannock et al., 1988; Habeshaw et al., 1991; Carmo-Peirera et al., 1987; Hoogstraten et al., 1976; O'Bryan et al., 1977; Forastiere et al., 1982; Focan et al., 1990 ). All but one highlighted an advantage in terms of response rate in standard dose arms, but none of these assessed the true role of dose intensity. In fact, analysing data from three studies with more than 100 patients each, two (Tannock et al., 1988; Focan et al., 1990) did not report any data about total dose delivered, while in the third (Habeshaw et al., 1991) , the significant increase in median dose intensity reported was associated with a significant increase in median total dose. A study conducted at the M.D. Anderson Clinic (Hortobagyi et al., 1987) , in which patients were randomised to receive a standard FAC or an escalated FAC (fluorouracil, adriamycin, cyclophosphamide) utilising a protected environment, failed to detect any difference either in response rate or in survival. This study is generally claimed as an example of failure of dose intensity, but it errs for the above-mentioned reason: the median dose, expressed in mg m-2 per cycle, was different in the two groups. Moreover, a subsequent analysis by the same authors (Hortobagyi et al., 1989) showed no significant difference in the dose intensity actually delivered, at 24 weeks, between high and standard dose arms. Indeed, it is not possible to assess the importance of cumulative dose independently of dose intensity. Experimental results (Skipper, 1990) indicate that cumulative dose and dose intensity may have independent and different effects. Therefore, to test the role of dose intensity it is important that planned and actual total administered dose are the same in both the control and the experimental groups of the study. This criterion was met in our study, in which patients in both groups received the same cumulative dose of chemotherapy and the same numbers of cycles.
The moderate increase in dose intensity obtained by acclerating CEF chemotherapy yielded an increase in response rate of borderline statistical significance. In addition, this response rate was higher than that obtained in two prior consecutive randomised trials carried out in our Institute (Conte et al., 1987; 1990) . When adjusted for prognostic factors, treatment retained its significant effect on response rate. Noteworthy was the fact that the effect of the dose intensity could be analysed without other confounding factors such as schedule, cumulative dose or drugs utilised. However, since anti-tumour response was not the primary objective of the study and given the small sample size, this result should be considered with caution.
In conclusion, the present study demonstrates that, with GM-CSF support, acceleration of the CEF regimen can be accomplished, achieving an almost 30% increase of dose intensity over the standard schedule. CEF acceleration is feasible and haematological toxicity is manageable for at least six courses in an outpatient setting.
